Fig. 1From: Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)The left panel shows MMDs and HIT-6 score variations from baseline to V6 in HFEM group. The right panel shows MHDs and HIT-6 score variations from baseline to V6 in CM patients. ** p < .001Back to article page